Sugi Predict

Sugi Predict / Compounds / SCHEMBL1551501

SCHEMBL1551501

SCHEMBL1551501

Cc1ccc(-n2c(C)nc3ccccc3c2=O)c(C)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 1.00
▸ L3MBTL1 Q9Y468 3/20 0.74
▸ LMNA P02545 2/20 0.74
▸ SMN1; SMN2 Q16637 2/20 0.72
▸ MAPT P10636 2/20 0.72
▸ KDM4E B2RXH2 1/20 0.72
▸ GLA P06280 1/20 0.64
▸ TDO2 P48775 1/20 0.61
▸ IDO2 Q6ZQW0 1/20 0.61
▸ POLB P06746 3/20 0.60
▸ HSD17B10 Q99714 1/20 0.56
▸ NPSR1 Q6W5P4 1/20 0.56
▸ HPD P32754 1/20 0.55
▸ TSHR P16473 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11445400 0.87 ALDH1A1 (0.78) ALDH1A1L3MBTL1LMNASMN1; SMN2MAPT
SCHEMBL11445652 0.86 ALDH1A1 (0.76) ALDH1A1L3MBTL1LMNASMN1; SMN2MAPT
SCHEMBL11702318 0.86 ALDH1A1 (0.76) ALDH1A1L3MBTL1LMNASMN1; SMN2MAPT
Methaqualone SCHEMBL43892 0.85 ALDH1A1 (1.00) ALDH1A1L3MBTL1LMNASMN1; SMN2MAPT
Methaqualone SCHEMBL29355239 0.85 ALDH1A1 (1.00) ALDH1A1L3MBTL1LMNASMN1; SMN2MAPT
Methaqualone SCHEMBL20471677 0.85 ALDH1A1 (1.00) ALDH1A1L3MBTL1LMNASMN1; SMN2MAPT
Methaqualone SCHEMBL29386732 0.85 ALDH1A1 (1.00) ALDH1A1L3MBTL1LMNASMN1; SMN2MAPT
SCHEMBL22736780 0.84 ALDH1A1 (0.72) ALDH1A1L3MBTL1LMNASMN1; SMN2MAPT
Methaqualone SCHEMBL3500629 0.84 ALDH1A1 (0.97) ALDH1A1L3MBTL1LMNASMN1; SMN2MAPT
Methaqualone SCHEMBL29849847 0.84 ALDH1A1 (0.97) ALDH1A1L3MBTL1LMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020006606-A1 A PHARMACEUTICAL COMPOSITION AND METHOD OF USE OF SAME HELIUM 3 RESOURCES PTY LTD (AU) 2020-01-09 — — WO claimed
US-12377235-B2 Multipurpose device INSTITUTE FOR CANCER RESEARCH (US) 2025-08-05 — — US disclosed
US-20250032419-A1 SOLID PHARMACEUTICAL COMPOSITIONS AND METHODS OF PRODUCING THE SAME GALVITA AG (CH) 2025-01-30 — — US disclosed
EP-4311543-A1 METHODS FOR LOADING TEMPLATE INVERTED CARRIERS Galvita AG (CH) 2024-01-31 — — EP disclosed
EP-4284347-A1 SOLID PHARMACEUTICAL COMPOSITIONS AND METHODS OF PRODUCING THE SAME Galvita AG (CH) 2023-12-06 — — EP disclosed
WO-2022162023-A1 SOLID PHARMACEUTICAL COMPOSITIONS AND METHODS OF PRODUCING THE SAME GALVITA AG (CH) 2022-08-04 — — WO disclosed
WO-2022160065-A1 FORMULATIONS INCLUDING DIHYDROHONOKIOL BETTERLIFE PHARMA INC. (CA) 2022-08-04 — — WO disclosed
US-11026920-B2 Use of NK-1 receptor antagonist serlopitant in pruritus VYNE THERAPEUTICS INC. (US) 2021-06-08 — — US disclosed
US-20210038842-A1 Multipurpose Device INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER 2021-02-11 — — US disclosed
US-20200306224-A1 USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS VYNE THERAPEUTICS INC. 2020-10-01 — — US disclosed
US-20160038462-A1 USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) 2016-02-11 — — US disclosed
US-9198898-B2 Use of NK-1 receptor antagonists in pruritus Tigercat Pharma, Inc. (US) 2015-12-01 — — US disclosed
US-20150057255-A1 USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) 2015-02-26 — — US disclosed
WO-2014209962-A1 USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS Tigercat Pharma, Inc. (US) 2014-12-31 — — WO disclosed
US-20120095104-A1 USE OF VASOCONSTRICTORS ZACHAR ORON (IL) 2012-04-19 — — US disclosed
EP-2376073-A2 DERMAL APPLICATION OF VASOCONSTRICTORS Zachar, Oron (IL) 2011-10-19 — — EP disclosed
US-20110144209-A1 USE OF VASOCONSTRICTORS ZACHAR ORON 2011-06-16 — — US disclosed
EP-2313037-A1 DERMAL APPLICATION OF VASOCONSTRICTORS Zachar, Oron (IL) 2011-04-27 — — EP disclosed
WO-2010063030-A2 DERMAL APPLICATION OF VASOCONSTRICTORS FEIGELSON, DANIEL (IL) 2010-06-03 — — WO disclosed
WO-2010001391-A1 DERMAL APPLICATION OF VASOCONSTRICTORS ZACHAR ORON (IL) 2010-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150057255-A1 USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS TACR1, CYSLTR1, HRH3 ALDH1A1 2009/4885L3MBTL1 3536/4885LMNA 4634/4885
US-20160038462-A1 USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS TACR1, CYSLTR1, HRH3 ALDH1A1 2009/4885L3MBTL1 3536/4885LMNA 4634/4885
US-20200306224-A1 USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS TACR1, CYSLTR1, NPSR1 ALDH1A1 2186/4885L3MBTL1 3785/4885LMNA 4634/4885
US-11026920-B2 Use of NK-1 receptor antagonist serlopitant in pruritus TACR1, CYSLTR1, NPSR1 ALDH1A1 2186/4885L3MBTL1 3785/4885LMNA 4634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.